Format

Send to

Choose Destination
Immunotherapy. 2016 May;8(5):665-74. doi: 10.2217/imt-2015-0020.

A network meta-analysis of the risk of immune-related renal toxicity in cancer patients treated with immune checkpoint inhibitors.

Author information

1
Clinical Oncology Department, Faculty of medicine, Ain Shams University, Lotfy Elsayed Street, Cairo, 11331, Egypt.
2
Medical Microbiology & Immunology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.

Abstract

BACKGROUND:

We performed a network meta-analysis of the risk of immune-related renal toxicity associated with immune checkpoint inhibitors.

METHODS:

Eligible studies included randomized trials of patients with immune checkpoint inhibitors; describing events of immune-related renal toxicity.

RESULTS:

Compared with chemotherapy control, immune checkpoint inhibitors carry a higher risk of all-grade (but not high-grade) immune-related renal toxicity. The risk with both nivolumab/ipilimumab combination was higher than the risk with either ipilimumab or nivolumab alone (odds ratio: 0.47 [95% credible interval: 0.21-0.99] and 0.11 [95% credible interval: 0.03-0.29]); for nivolumab/ipilimumab combination versus ipilimumab or nivolumab monotherapy).

CONCLUSION:

Our meta-analysis demonstrated that the use of immune checkpoint inhibitors is associated with an increased risk of all-grade immune-related renal toxicity compared with chemotherapy control.

KEYWORDS:

ipilimumab; nephritis; nivolumab; pembrolizumab

PMID:
27140415
DOI:
10.2217/imt-2015-0020
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center